CCCC

C4 Therapeutics, Inc.
CAPPED RATING

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

C4 Therapeutics, Inc. (CCCC) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B-); its weakest is Growth (D).

Quantitative Factor Evaluation • Updated

Overall Rating
2.4 / 5.0
C
Value
B-
Factor Score 2.9 / 5.0
Growth
D
Factor Score 1.3 / 5.0
Profitability
C+
Factor Score 2.7 / 5.0
Momentum
C+
Factor Score 2.6 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -3.5
EV / EBITDA -2.4
Rev Growth YoY -24.6%
Gross Margin 88.8%
Price Return 3M -23.1%
Price Return 12M 28.2%
Catalyst Signal 0.00
Market Cap $394.0M
TTM Revenue $32.3M
Price / Sales 12.2
ROE -47.6%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 B- (2.9) D (1.3) C+ (2.7) C+ (2.6) C+ (2.6) C (2.4)
2026-11-04 B- (3.0) D+ (1.6) C+ (2.7) C+ (2.7) C+ (2.7) C+ (2.5)
2026-10-28 B- (3.0) D+ (1.6) C+ (2.7) C+ (2.8) C+ (2.7) C+ (2.5)
2026-10-21 B- (3.0) D+ (1.6) C+ (2.7) C+ (2.6) C+ (2.6) C (2.5)
2026-10-14 B- (3.0) D+ (1.6) C+ (2.7) C+ (2.8) C+ (2.6) C+ (2.5)
Page 1 of 8
…